Keros stock price target cut on study termination By Investing.com
On Thursday, Oppenheimer adjusted its price target on Keros Therapeutics (NASDAQ:KROS) shares, reducing it significantly to $23.00 from the previous target of $63.00. The stock, currently trading at $10.42, has experienced a dramatic 80% decline over the past year, with a particularly sharp 30% drop in the past week.
Despite this change, the firm maintained its Outperform rating on the biotechnology company’s stock. According to InvestingPro analysis, the stock appears undervalued based on its Fair Value calculations.
The revision follows Keros Therapeutics’ announcement on Wednesday that it had voluntarily terminated the Phase 2 TROPOS study for the treatment of pulmonary arterial hypertension (PAH) with its drug cibotercept. This…
